Immix Biopharma Achieves 95% Complete Response Rate in NEXICART-2 Phase 2 CAR-T Trial

A 95% complete response rate in a registrational-design Phase 2 trial positions Immix Biopharma closer to a BLA submission for NXC-201, its sterically-optimized BCMA-targeted CAR-T therapy, and sharpens the manufacturing and quality readiness questions that plant heads and CMC leads will need to answer before that filing lands.

In an interim update from NEXICART-2 (NCT06097832), the company reported that all four MRD-negative patients presented at ASH 2025 have since converted to complete response, bringing the trial's CR rate to 19 of 20 patients. All complete responses were achieved within one year of follow-up post-dosing, and no relapses have been observed among patients who reached CR. All subsequently enrolled patients with available MRD results are MRD-negative at the one-month mark. The trial is enrolling toward a 45-patient target.

For QA directors and regulatory affairs leads, the timeline is the operative variable. The company expects to present one-year follow-up data on enrolled patients by end of March 2027, with that dataset described as the trigger for BLA submission and commercial launch. A further NEXICART-2 data update is scheduled for late September 2026. That cadence leaves a defined but compressed window for process validation, lot release strategy, and the sterility assurance documentation that 21 CFR Part 211 and ICH Q10 require for a CAR-T product moving from clinical to commercial scale.

NXC-201 carries FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, alongside Orphan Drug Designation from both the FDA and EMA. RMAT status enables earlier and more frequent FDA engagement on CMC topics, a lever that manufacturing teams should be actively using given the March 2027 data readout target. The therapy's autologous CAR-T nature introduces apheresis-to-release chain-of-identity controls, cryopreservation validation, and patient-specific lot documentation requirements that are distinct from conventional biologics and demand early alignment with the agency.

The company also indicated plans to initiate a multi-center, randomized Phase 3 trial in newly diagnosed AL Amyloidosis patients, a population broader than the heavily pretreated relapsed/refractory cohort in NEXICART-2, where patients had a median of four prior lines of therapy. Scaling manufacturing capacity to support a frontline indication while simultaneously managing a BLA submission represents a concurrent operational challenge that supply-chain and quality teams should be scoping now.

The September 2026 data update will serve as the next measurable checkpoint for assessing whether the CR rate holds as enrollment completes and follow-up matures toward the one-year threshold required for the BLA dataset.

Source: Immix Biopharma via GlobeNewswire, May 21, 2026.